Emgrast M 250mcg Injection
By Emgrast M
Rx
1 Injection in a Vial

Composition
Sargramostim(250mcg)

Manufacturer - Emcure Pharmaceuticals Ltd
255/2, Hinjawadi, Pune - 411057, India

Expires on or after
February, 2027

liver
Caution should be taken when using Emgrast M 250mcg Injection in patients with liver disease. It may be necessary to adjust the dose of the medication in these cases. It is important to consult your doctor before using this injection. Regular monitoring of liver function tests is recommended while you are taking Emgrast M 250mcg Injection.

kidney
Emgrast M 250mcg Injection should be used cautiously in patients with kidney disease. Dose adjustment may be necessary, so consult your doctor. Regular monitoring of kidney function tests is recommended during treatment.

alcohol
It is uncertain if consuming alcohol with Emgrast M 250mcg Injection is safe. Please consult your doctor when drinking alcohol with this injection.

driving
Caution should be exercised while driving when using Emgrast M 250mcg Injection. If you notice any symptoms that may impact your focus or reaction time, refrain from driving.

pregnancy
Emgrast M 250mcg Injection may not be safe during pregnancy. Limited human studies and animal research indicate potential harm to the developing baby. Your doctor will assess the benefits and risks before prescribing. Please consult your doctor before using Emgrast M Injection.

breastfeeding
Emgrast M 250mcg Injection is likely safe while breastfeeding with limited data showing no notable risk to the baby.
Habit Forming | No |
Chemical Class | Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) |
Therapeutic Class | - |
Action Class | Granulocyte-macrophage colony stimulating factor (GM-CSF) |
₹1615.37
Inclusive of all taxes
Content verified by

Dr. Monie Riju Simon
MBBS - General Medicine
Last update on 11-Feb-2025